Detalhe da pesquisa
1.
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Invest New Drugs
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483782
2.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Blood
; 135(13): 996-1007, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977002
3.
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Invest New Drugs
; 40(4): 762-772, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35467243
4.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143969
5.
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.
Future Oncol
; 17(6): 637-648, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33300372
6.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 20(5): 711-718, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922731
7.
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Oncology
; 97(2): 102-111, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31230047
8.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29533458
9.
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.
Oncologist
; 23(6): 658-e72, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29511132
10.
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
Invest New Drugs
; 35(2): 189-197, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28111727
11.
Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study.
Cancer Chemother Pharmacol
; 93(4): 329-339, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38036720
12.
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
Clin Cancer Res
; 30(3): 506-521, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971712
13.
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Cancer Chemother Pharmacol
; 92(1): 15-28, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37219686
14.
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Cancers (Basel)
; 14(20)2022 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36291780
15.
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(1): 57-70, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34598945
16.
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Cancer Chemother Pharmacol
; 89(1): 93-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750637
17.
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.
Target Oncol
; 17(2): 125-138, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35347559
18.
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
Lung Cancer
; 159: 162-170, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34371366
19.
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Clin Transl Sci
; 14(1): 277-287, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32770720
20.
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
J Clin Oncol
; 38(11): 1154-1163, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31961766